Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

The Prevalence of Metabolic Syndrome in Inpatients with Schizophrenia

정신분열병 입원 환자에서의 대사 증후군 유병률 연구

  • Received : 2010.12.14
  • Accepted : 2011.01.24
  • Published : 2011.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : The objective of this study is to assess the prevalence and risk factors of metabolic syndrome (MS) among inpatients with schizophrenia, and to compare with general population. Methods : Nine hundreds seventy inpatients were included to assess the prevalence of MS from two mental hospitals in Yong-in city. Assessment of MS was performed based on modified American Heart Association criteria with abdominal obesity threshold of 90cm for men, 85cm for women. Comparative analysis was performed using age- and gender matched sample from Korea Health and Nutritional Examination Survey III. For evaluating risk factors, analysis included 766 inpatients taking consistent medications at least for 30 days. Results : The prevalence of MS of inpatients with schizophrenia was 26.2%, in females it was 33.2%, compared to 20.2% in males(p < 0.001). Compared to general population, the prevalence of MS was significantly lower in male and higher in female patients. In terms of criteria prevalence, who met abdominal circumference criterion were more prevalent in patient group(p < 0.001). After multivariate analysis, female gender and old age remained as risk factors of MS. Conclusions : The prevalence of MS of inpatients with schizophrenia was 26.2% and significantly low compared to general population. Female gender and old age were risk factors of MS.

Keywords

References

  1. Marder SR, Essock SM, Miller AL, Buchanan RW, Caey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-1349. https://doi.org/10.1176/appi.ajp.161.8.1334
  2. Osby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stokholm county, Sweden. Schizophr Res 2000;45:21-28. https://doi.org/10.1016/S0920-9964(99)00191-7
  3. Kylin E. Studien ueber das hypertonie-hyperglykmie-hyperurikmiesyndrome. Zentralblatt Fuer Innere Med 1923;44:105-127.
  4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
  5. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome--a new worldwide definition. Lancet 2005;366:1059-1062. https://doi.org/10.1016/S0140-6736(05)67402-8
  6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults(Adult Treatment Panel III). JAMA 2001;285:2486-2497. https://doi.org/10.1001/jama.285.19.2486
  7. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735-2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404
  8. Choi KM, Kim SM, Kim YE, Choi DS, Baik SH, Lee J; International Diabetes Federation. Prevalence and cardiovascular disease risk of the metabolic syndrome using National Cholesterol Education Program and International Diabetes Federation definitions in the Korean population. Metabolism 2007; 56:552-558. https://doi.org/10.1016/j.metabol.2006.12.003
  9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359. https://doi.org/10.1001/jama.287.3.356
  10. Ford ES, Li C, Zhao G , Pearson WS, Mokdad AH. Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation. Diabetes Care 2008;31:587-589. https://doi.org/10.2337/dc07-1030
  11. Pan WH, Yeh WT, Weng LC. Epidemiology of metabolic syndrome in Asia. Asia Pac J Clin Nutr 2008;17 Suppl 1:37-42.
  12. Park HS, Kim SM, Lee JS, Lee J, Han JH, Yoon DK, et al. Prevalence and trends of metabolic syndrome in Korea: Korean National Health and Nutrition Survey 1998-2001. Diabetes Obes Metab 2007;9:50-58. https://doi.org/10.1111/j.1463-1326.2005.00569.x
  13. Seo I, Kim H, Ahn S, Oh S, Yoon Y. In-Depth Analysis on the 3rd Korea Health and Nutrition Examination Survey 2007:167-193.
  14. Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diabetes Res Clin Pract 2007;75:72-80. https://doi.org/10.1016/j.diabres.2006.04.013
  15. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness(CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32. https://doi.org/10.1016/j.schres.2005.07.014
  16. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119:4-14. https://doi.org/10.1111/j.1600-0447.2008.01317.x
  17. Nam YY, Kim CS, Ahn CW, Park KM, Ryu B, Kim CH. Clinical correlates of metabolic syndrome in patients with chronic schizophrenia. Korean J Psychopharmacol 2006;17:335-341.
  18. Yoon BH, Bae A, Park SH, Jung KY, Bahk WM. Prevalence and Characteristics of Metabolic Syndrome in Schizophrenic Inpatient. Abstracted presented at the Korea Neuropsychiatric Association Annual Meeting Seoul; 2008.
  19. Lee NY, Kim SK, Kim SH, Kang U, Kim YS, Ahn YM. Metabolic syndrome in patients with Schizophrenia and Bipolar disorder: comparision with general population. Abstracted presented at the Korea Neuropsychiatric Association Annual Meeting Seoul;2008.
  20. Association AP. Diagnostic and Statistical Manual of Mental Disorders(DSM-IV-TR). 4th evidence-based text revision ed. Washington, DC: American Psychiatric Association; 2000.
  21. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007;29:330-336. https://doi.org/10.1590/S1516-44462007000400007
  22. Garland EJ, Remick RA, Zis AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988;8:323-330.
  23. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004;65 Suppl 18:13-26.
  24. Sadock BJ, Sadock VA. Synopsis of Psychiatry. 10 ed. Philadelphia, PA: Lippincott Williams & Wilkins;2007. p.1046.
  25. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667. https://doi.org/10.4088/JCP.v64n0607
  26. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G . Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-760. https://doi.org/10.1177/070674370404901106
  27. Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR. Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med 2008;38:103-112. https://doi.org/10.2190/PM.38.1.j
  28. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68 Suppl 4:8-13. https://doi.org/10.4088/JCP.0307e08
  29. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220. https://doi.org/10.4088/JCP.v60n0402
  30. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002;55:277-284. https://doi.org/10.1016/S0920-9964(01)00256-0
  31. Batsis JA, Nieto-Martinez RE, Lopez-Jimenez F. Metabolic syndrome: from global epidemiology to individualized medicine. Clin Pharmacol Ther 2007;82:509-524. https://doi.org/10.1038/sj.clpt.6100355
  32. De Hert M, Schreurs V, Vancampfort D, VAN Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009;8:15-22. https://doi.org/10.1002/j.2051-5545.2009.tb00199.x
  33. Reynolds MF, Sisk EC, Rasgon NL. Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: a review. Curr Med Chem 2007;14:2799-2812. https://doi.org/10.2174/092986707782360088
  34. Suvisaari JM, Saarni SI, Perala J, Suvisaari JV, Harkanen T, Lonnqvist J, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007;68:1045-1055. https://doi.org/10.4088/JCP.v68n0711